NCT00193687已完成3 期
An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 986
研究概览
简要总结
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient setting for long-term bifeprunox treatment
排除标准
- •current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of substance abuse, uncontrolled hypertension
研究者
相似试验
已完成
3 期
Bifeprunox in the Treatment of SchizophreniaSchizophreniaNCT00193713Solvay Pharmaceuticals
终止
3 期
Study Evaluating Bifeprunox in Patients With Schizophrenia.SchizophreniaNCT00366327Wyeth is now a wholly owned subsidiary of Pfizer400
已完成
2 期
Safety and Tolerability Study of Drug to Treat SchizophreniaSchizophreniaNCT00044005Sumitomo Pharma America, Inc.98
招募中
3 期
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaSchizophreniaNCT05184335Reviva Pharmaceuticals690
终止
3 期
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypePsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeNCT00160147Solvay Pharmaceuticals60